These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17617654)

  • 41. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence.
    Taylor AP; Rodriguez M; Adams K; Goldenberg DM; Blumenthal RD
    Int J Cancer; 2003 Jun; 105(2):158-64. PubMed ID: 12673673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
    Ahmad S; Ahmed A
    Circ Res; 2004 Oct; 95(9):884-91. PubMed ID: 15472115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preeclampsia -- searching for the cause.
    Solomon CG; Seely EW
    N Engl J Med; 2004 Feb; 350(7):641-2. PubMed ID: 14764924
    [No Abstract]   [Full Text] [Related]  

  • 44. Expression of placenta growth factor (PIGF) in ischaemic retinal diseases.
    Yamashita H; Eguchi S; Watanabe K; Takeuchi S; Yamashita T; Miura M
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():372-4. PubMed ID: 10624438
    [No Abstract]   [Full Text] [Related]  

  • 45. [New insights in the pathophysiology of preeclampsia and potential therapeutic implications].
    Boulanger H; Flamant M
    Nephrol Ther; 2007 Dec; 3(7):437-48. PubMed ID: 18047998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy.
    Llurba E; Crispi F; Verlohren S
    Fetal Diagn Ther; 2015; 37(2):81-92. PubMed ID: 25659427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders.
    Sgambati E; Marini M; Zappoli Thyrion GD; Parretti E; Mello G; Orlando C; Simi L; Tricarico C; Gheri G; Brizzi E
    BJOG; 2004 Jun; 111(6):564-70. PubMed ID: 15198784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia.
    Maynard SE; Venkatesha S; Thadhani R; Karumanchi SA
    Pediatr Res; 2005 May; 57(5 Pt 2):1R-7R. PubMed ID: 15817508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Placental overexpression of transforming growth factor-beta3 in the HELLP syndrome.
    Emanuelli M; Giannubilo SR; Landi B; Sartini D; Pierella F; Corradetti A; Tranquilli AL
    Gynecol Obstet Invest; 2008; 65(1):1-5. PubMed ID: 17671384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome.
    Sliwa K; Mebazaa A
    Eur Heart J; 2014 Mar; 35(11):680-2. PubMed ID: 24302271
    [No Abstract]   [Full Text] [Related]  

  • 51. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preeclampsia: a renal perspective.
    Karumanchi SA; Maynard SE; Stillman IE; Epstein FH; Sukhatme VP
    Kidney Int; 2005 Jun; 67(6):2101-13. PubMed ID: 15882253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The importance of angiogenic markers in the differential diagnosis of HELLP syndrome vs. non-HELLP thrombocytopenia.
    Quirós C; Suárez F; Prieto B; Rodriguez V; Vaquerizo Ó; Álvarez Menéndez FV
    Clin Chem Lab Med; 2016 Jul; 54(7):e187-9. PubMed ID: 26581071
    [No Abstract]   [Full Text] [Related]  

  • 54. Urinary placental growth factor and risk of preeclampsia.
    Levine RJ; Thadhani R; Qian C; Lam C; Lim KH; Yu KF; Blink AL; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    JAMA; 2005 Jan; 293(1):77-85. PubMed ID: 15632339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis.
    Larcher F; Franco M; Bolontrade M; Rodriguez-Puebla M; Casanova L; Navarro M; Yancopoulos G; Jorcano JL; Conti CJ
    Mol Carcinog; 2003 Jun; 37(2):83-90. PubMed ID: 12766907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis.
    Barillari G; Albonici L; Franzese O; Modesti A; Liberati F; Barillari P; Ensoli B; Manzari V; Santeusanio G
    Am J Pathol; 1998 May; 152(5):1161-6. PubMed ID: 9588884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathogenesis of preeclampsia.
    Sircar M; Thadhani R; Karumanchi SA
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):131-8. PubMed ID: 25636145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenesis in gestational vascular complications.
    Yagel S
    Thromb Res; 2011 Feb; 127 Suppl 3():S64-6. PubMed ID: 21262445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in understanding of preeclampsia.
    Bdolah Y; Karumanchi SA; Sachs BP
    Croat Med J; 2005 Oct; 46(5):728-36. PubMed ID: 16158464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.
    Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.